MX2022001083A - Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer. - Google Patents
Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer.Info
- Publication number
- MX2022001083A MX2022001083A MX2022001083A MX2022001083A MX2022001083A MX 2022001083 A MX2022001083 A MX 2022001083A MX 2022001083 A MX2022001083 A MX 2022001083A MX 2022001083 A MX2022001083 A MX 2022001083A MX 2022001083 A MX2022001083 A MX 2022001083A
- Authority
- MX
- Mexico
- Prior art keywords
- palm
- treatment
- chemotherapy
- peripheral neuropathy
- cipn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
- A61K47/6909—Micelles formed by phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
La presente descripción proporciona un método para el tratamiento o la prevención de la neuropatía periférica inducida por la quimioterapia (CIPN, por sus siglas en inglés) en un paciente con cáncer tratado con, o que vaya a tratarse con, un agente quimioterapéutico que provoque CIPN; el método comprende: administrar una cantidad terapéuticamente efectiva de una composición que contiene una nanopartícula de micela lipídica anfifílica peptídica (PALM, por sus siglas en inglés) al paciente con cáncer, donde la nanopartícula de PALM comprende una PALM que contiene el agente quimioterapéutico que provoca CIPN, y donde la PALM comprende un péptido, y un componente lipídico que comprende esfingomielina y uno o más fosfolípidos adicionales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962886282P | 2019-08-13 | 2019-08-13 | |
PCT/US2020/045785 WO2021030359A1 (en) | 2019-08-13 | 2020-08-11 | Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001083A true MX2022001083A (es) | 2022-05-18 |
Family
ID=74571179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001083A MX2022001083A (es) | 2019-08-13 | 2020-08-11 | Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4013444A4 (es) |
JP (1) | JP2022544262A (es) |
KR (1) | KR20220045203A (es) |
CN (1) | CN114401736A (es) |
AU (1) | AU2020329923A1 (es) |
CA (1) | CA3147790A1 (es) |
IL (1) | IL290487A (es) |
MX (1) | MX2022001083A (es) |
WO (1) | WO2021030359A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116019911B (zh) * | 2022-11-11 | 2023-11-28 | 海南大学 | 一种基于功能化二氧化硅并携载诊疗试剂的纳米颗粒及其制备方法与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080045559A1 (en) * | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
US9233163B2 (en) * | 2010-12-28 | 2016-01-12 | The Children's Hospital Of Philadelphia | Hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
BR112014031421A2 (pt) * | 2012-06-15 | 2017-06-27 | Brigham & Womens Hospital Inc | composições para tratamento de câncer e métodos para produção das mesmas |
WO2015112902A2 (en) * | 2014-01-23 | 2015-07-30 | Sova Pharmaceuticals, Inc. | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN |
US10426753B2 (en) * | 2014-04-03 | 2019-10-01 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
US10532105B2 (en) * | 2015-07-10 | 2020-01-14 | Peptinovo Biopharma, LLC. | Formulations for improving the efficacy of hydrophobic drugs |
JP2018521068A (ja) * | 2015-07-15 | 2018-08-02 | セレーター ファーマシューティカルズ インコーポレイテッド | 改善されたナノ粒子送達系 |
CN109310702A (zh) * | 2016-05-20 | 2019-02-05 | 芝加哥大学 | 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒 |
-
2020
- 2020-08-11 MX MX2022001083A patent/MX2022001083A/es unknown
- 2020-08-11 CA CA3147790A patent/CA3147790A1/en active Pending
- 2020-08-11 EP EP20851766.4A patent/EP4013444A4/en active Pending
- 2020-08-11 JP JP2022508753A patent/JP2022544262A/ja active Pending
- 2020-08-11 CN CN202080064877.0A patent/CN114401736A/zh active Pending
- 2020-08-11 KR KR1020227007849A patent/KR20220045203A/ko unknown
- 2020-08-11 AU AU2020329923A patent/AU2020329923A1/en active Pending
- 2020-08-11 WO PCT/US2020/045785 patent/WO2021030359A1/en unknown
-
2022
- 2022-02-09 IL IL290487A patent/IL290487A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4013444A4 (en) | 2023-11-01 |
AU2020329923A1 (en) | 2022-02-24 |
EP4013444A1 (en) | 2022-06-22 |
JP2022544262A (ja) | 2022-10-17 |
IL290487A (en) | 2022-04-01 |
CA3147790A1 (en) | 2021-02-18 |
WO2021030359A1 (en) | 2021-02-18 |
KR20220045203A (ko) | 2022-04-12 |
CN114401736A (zh) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
IN2015DN00376A (es) | ||
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
NZ604031A (en) | Methods of treatment of pancreatic cancer | |
JO3709B1 (ar) | تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
FR2949044B1 (fr) | Composition comprenant une fraction d'insaponifiable | |
IN2012DN02137A (es) | ||
MX2021006751A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
MA34815B1 (fr) | Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer | |
MX2020011295A (es) | Tratamiento de dermatitis atopica. | |
MX2022001083A (es) | Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
MX2023007080A (es) | Metodo para el tratamiento de la fibrosis. | |
MX2020001254A (es) | Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. | |
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
MX2022012967A (es) | Tratamiento de la hidradenitis supurativa. | |
MX2022005596A (es) | Regimen de dosificacion para agentes anti-dll3. |